Abstract. In order to clarify the molecular mechanism involved in renal carcinogenesis, and to identify molecular targets for diagnosis and treatment, we analyzed genome-wide gene expression profiles of 15 surgical specimens of clear cell renal cell carcinoma (RCC), compared to normal renal cortex, using a combination of laser microbeam microdissection (LMM) with a cDNA microarray representing 27,648 genes. We identified 257 genes that were commonly up-regulated and 721 genes that were down-regulated in RCCs. None of top 24 up-regulated genes that showed most significant differences in informative RCC-cases were included in previous reports describing expression profiles of RCC using RNAs isolated from bulk tissues. These findings suggest that it is important to purify as much as possible the populations of cancerous and normal epithelial cells obtained from surgical specimens. Among the significantly-transactivated genes, we focused on Semaphorin 5B (SEMA5B) and knocked-down its expression in RCC cells by small-interfering RNA (siRNA). Effective downregulation of its expression levels in RCC cells significantly attenuated RCC cell viability. In conclusion, our data should be helpful for a better understanding of the tumorigenesis of RCC and should contribute to the development of diagnostic tumor markers and molecular-targeting therapy for patients with RCC.
Introduction
Renal cell carcinoma (RCC) accounts for approximately 3% of all malignancies (1). At present, renal cell carcinoma at an early stage can be curable by surgical resection, which is the most effective treatment for localized RCC tumors. However, no effective treatment option is available to patients at an advanced stage because this disease is usually resistant to both chemotherapy and radiotherapy. The proportion of the patients showing good response to chemotherapy alone is 4-6% (2). Although immunotherapy is also available, the response rate is limited to 10-15% and severe adverse reactions are often observed; for example, about 14% of the cases with metastatic RCC respond to a single treatment of interferon-· (3). Hence, no significant improvement of overall prognosis of patients with this disease has been observed.
The prognosis of RCC is influenced most significantly by tumor stage and histological grade (2) (3) (4) (5) (6) . At present the diagnosis of RCC is made by imaging tools such as ultrasonography and computed tomography, but any tumor markers specific to RCC are not yet available in general clinical practice for diagnosis. Histopathologically, RCC is considered to be a mixture of heterogeneous diseases and constitutes from various distinct histological types such as clear cell (70%), papillary (15-20%) , chromophobe (4-6%), collecting duct (<1%) and unclassified (4-5%) (7) .
We chose the most predominant type, clear cell renal cell carcinoma (ccRCC), for this study and performed genomewide expression profile analysis of ccRCC. We studied the gene expression profiles of 15 ccRCC cells using cDNA microarrays consisting of 27,648 genes in a combination with laser microbeam microdissection technology to collect pure populations of ccRCC cells as well as non-cancerous renal cortex cells. Genome-wide gene expression profiles of tumors can provide comprehensive information of molecular mechanism underlying renal carcinogenesis, and possibly lead to find molecular tumor markers that are applicable for earlier diagnosis and also serve as targets for development of novel effective therapies.
Laser microbeam microdissection, extraction of RNA and T7-based RNA amplification. Preparation of sections, laser microbeam microdissection (LMM), extraction of total RNA, T7-based amplification, and labeling of probes were performed as described previously (8) . Like many solid tumors, RCCs contain other cell types in addition to carcinoma cells. Especially, ccRCC is generally well vascularized, and infiltrating immune cells are frequently seen on histological sections. To obtain precise gene expression profiles of cancer cells, we used LMM technology to collect pure populations of ccRCC cells as well as non-cancerous renal cortex. A mixture of normal renal cortex cells in kidney tissues from 11 patients was prepared as a universal control. To guarantee the quality of RNAs, total RNA extracted from adjacent frozen tissue of each case were electrophoresed on a denaturing agarose gel, and the quality was validated by the presence of rRNA bands. We labeled 2.5 μg aliquots of RNA amplified by the T7-RNA amplification method from each cancerous or non-cancerous tissue sample, respectively, with Cy5-dCTP or Cy3-dCTP (Amersham Biosciences, Buckinghamshire, UK).
cDNA microarray and analysis of data. The procedures for hybridization, washing, scanning (detection of signals), and normalization of data were carried out as previously described (9) . We fabricated a genome-wide cDNA microarray containing 27,648 cDNAs selected from the UniGene Database of the National Center for Biotechnology Information. We quantified the signal intensities of Cy3 and Cy5 from the 27,648 spots and analyzed the signals by substituting backgrounds, using ArrayVision software (Imaging Research, Inc., St. Catharines, Ontario, Canada). Subsequently, the fluorescence intensities of Cy5 (RCC tumor) and Cy3 (control) for each target spot were adjusted so that the mean Cy5/Cy3 ratio of the 52 housekeeping genes became one. Because data derived from lowsignal intensities are less reliable, we determined a cut-off value on each slide, and we excluded genes from further analysis when both the Cy3 and the Cy5 dyes yielded signal intensities lower than that of the cut-off. For other genes, we calculated the Cy5/Cy3 ratio using the raw data of each sample. After leaving out the unreliable spots, we selected up-regulated or down-regulated genes based on their Cy5/Cy3 ratios (r): up-regulated (r >5.0) and down-regulated (r <0.2).
Identification of genes that were up-or down-regulated
commonly from normal renal cortex to RCC. We defined genes, that revealed altered expression in ccRCCs according to the following criteria: a) genes for which we were able to obtain expression data >50% of the cases examined; and b) genes whose expression ratio was >5.0 or <0.2 in >50% of informative cases.
Semi-quantitative reverse transcription-PCR.
RNAs from the purified populations of ccRCC cells and from normal renal cortex cells were extracted using RNeasy Micro Kits (Qiagen, Valencia, CA) and were treated with DNase I according to the recommendation of the manufacturer. Extracted RNAs were subjected to two rounds of RNA amplification using Table I . Clinicopathological features of ccRCC clinical samples used for cDNA microarray analysis.
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T7-based in vitro transcription (Epicentre Technologies, Madison, WI), and amplified RNAs were reverse transcribed to single-stranded cDNAs using random primer with Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA). We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR amplification and monitored their reactions using Farnesyl-diphosphate farnesyl-transferase 1 (FDFT1) as a quantitative control because this showed the smallest Cy5/Cy3 fluctuations in our RCC-microarray data. PCR amplification was performed using single-strand cDNAs as templates and gene specific primers (Table II ). To examine the expression level of SEMA5BV1 and SEMA5BV2 in RCC cells, we performed RT-PCR experiments using the following primer sets: 5'-CTGGAAACAGCAGCCAGAG-3' and 5'-CAGTGCTGGCAAGACAGGTA-3'. PCR reactions were optimized for the number of cycles to ensure product intensity within the logarithmic phase of amplification.
Northern blot analysis. For Northern blot analysis, a 1 μg aliquot of each mRNA isolated using mRNA Purification Kit (Amersham Biosciences) and human normal-tissue polyA(+) RNAs (Clontech, Palo Alto, CA) were separated on a 1% denaturing agarose gel and transferred to a nylon membrane.
Human multiple tissue northern (MTN) blots (BD Biosciences, Palo Alto, CA) as well as our own RCC blots containing mRNA from 11 RCC cell lines (Caki-1, Caki-2, 786-O, A-498, ACHN, 769-P, A-704, RXF-631L, OS-RC-2, TUHR10TKB, and TUHR14TKB), four normal organs (heart, lung, liver and kidney) and normal renal proximal tubule epithelial cells (RPTEC), were hybridized for 16 h with a 32 P-labeled PCR product of SEMA5B cDNA. The cDNA probes of SEMA5B were prepared by RT-PCR using the primers 5'-CTGTGGA CCTACTGGGCATT-3' and 5'-GTGTGTGTTCCTGAACA GATGAA-3'. Pre-hybridization, hybridization and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at -80˚C for 14 days.
Effect of small-interfering RNA on growth of RCC cells.
To evaluate the biological functions of SEMA5B in RCC cells, we used a psi-U6BX3.0 vector for expression of short-hairpin RNA against the target gene, as described previously (10) . The U6 promoter was cloned upstream of the gene-specific sequence (19- nucleotide sequence from the target transcript, separated from the reverse complement of the same sequence by a short spacer, TTCAAGAGA), with five thymidines as a Table II. Primer sequences for semi-quantitative RT-PCR experiments.  -----------------------------------------------------------------------------------------------------Gene Forward primer Reverse primer Table III . Sequences of specific double-stranded oligonucleotides inserted into siRNA expression vector.
termination signal and a neo-cassette for selection by Geneticin (Sigma). Plasmids designed to express small interfering RNA (siRNA) were prepared by cloning of double-stranded oligonucleotides into psi-U6BX vector (Table III) . Human RCC cell line, OS-RC-2, which express SEMA5B at a high level, were plated onto 10-cm dishes (1x10 6 cells per dish), and transfected with psiU6BX vectors that included the target sequences for scramble sequences, SEMA5B using Lipofectamine 2000 (Invitrogen). The transfected OS-RC-2 cells were selected in medium containing 0.7 mg/ml of neomycin (Geneticin; Gibco BRL, Carlsbad, CA). Next, total RNA was extracted from the cells at 5 days after Geneticin selection, and then the knockdown effect of siRNAs was examined by a semi-quantitative RT-PCR using specific primer sets: forward, 5'-AACTTAGAGGTGGGGAGCAG-3' and reverse, 5'-CACAACCATGCCTTACTTTATC-3' as an internal control, and 5'-TGACCTGTGCTTAGAAGTCCTTT-3' and 5'-CTGTGTGTTCCTGAACAGATGAA-3' for SEMA5B. In 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, cell viability was evaluated using Cell-counting kit-8 (DOJINDO, Kumamoto, Japan) at 7 or 14 days after the transfection according to the protocol of the supplier. After 21 days of the incubation, these cells were fixed with 4% paraformaldehyde, and stained with Giemsa solution for colony formation assay.
Results
Identification of commonly up-regulated or down-regulated genes in ccRCCs.
We carried out LMM to purify cancer cells from tumor tissue and also normal renal cortex cells as controls (Fig. 1) , and performed gene expression analysis using cDNA microarray consisting of 27,648 cDNA sequences. We then selected genes from our data set according to the criteria that the Cy5/Cy3 ratio of a given gene was >5.0 in >50% of informative cases (see Materials and methods). Using this filter, we identified 257 genes that were commonly upregulated in ccRCC compared with normal renal cortex cells (Table IV) . Among them, the biological functions of 182 genes were already known to some extent. Of them, HIG2 (hypoxia inducible gene 2), NNMT (nicotinamide N-methyltransferase), IGFBP3 (insulin-like growth factor binding protein 3), VEGF (vascular endothelial growth factor), and VWF (Von Willebrand factor) had already been reported as genes involved in renal tumorigenesis (11) (12) (13) (14) (15) , supporting the high quality of our microarray data. The up-regulated genes represented a variety of functions including genes associated with signal-transduction pathways (ADORA3, EDA2R), or genes involved in various metabolic pathways (SCD, ENPP3), transport systems (SLC1A3, ABCG1), angiogenesis (VEGF), apoptosis (FTS), and cell adhesion (CDH2). In particular, 92 of the up-regulated genes were expressed at a level >10-fold higher than in normal cortex cells; for example, ADORA3 (adenosine A3 receptor), SLC1A3 (solute carrier family 1, member 3) and STC2 (stanniocalcin 2) were up-regulated >10-fold in >90% of the informative cases.
We also identified 721 genes whose expression ratios were <0.2 in ≥50% of the informative ccRCCs (Table V) . Among these down-regulated genes, 532 genes had been functionally characterized to some extent. They included WT1 (Wilms tumors 1), CDKN1C (cyclin-dependent kinase inhibitor 1C), and GAS1 (growth arrest-specific 1), which have been implicated in growth suppression or apoptosis (16) (17) (18) (19) . In particular, WT1 and CDKN1C were significantly down-regulated in all the 15 RCC cases, and GAS1 was also significantly down-regulated in 14 of 15 cases, indicating down-regulation of those genes may be related to RCCtumorigenesis.
To further validate the expression data obtained by RCCmicroarray analysis, we performed semi-quantitative RT-PCR Table IV . Genes commonly up-regulated in RCCs. Table IV . Continued. Table IV . Continued. Table IV . Continued. Table IV . Continued. 
We selected genes whose normalized expression ratios (RCC/normal renal cortex cells) were >5.0 in more than 50% of the 15 RCC cases examined. Accession numbers, gene symbols, and gene names were retrieved from the Unigene Database.
- Table V . Genes commonly down-regulated in RCC. Table V . Continued. Table V . Continued. Table V . Continued. Table V . Continued. Table V . Continued. Table V . Continued. Table V. Continued. Table V . Genes commonly down-regulated in RCC. experiments for 6 genes that were most significantly overexpressed in almost all of the informative cases: ADORA3, SLC1A3, STC2, ENPP3, VWF, and NNMT. The results of the semi-quantitative RT-PCR analysis were highly concordant with the microarray data in the great majority of the tested cases (Fig. 2) .
-----------------------------------------------------------------------------------------------------
Identification of semaphorin 5B (SEMA5B) as a molecular target for ccRCC therapy. Among the up-regulated genes in RCC, we focused on semaphorin 5B, SEMA5B, for further biological analysis because it was overexpressed very commonly in RCC, but not expressed in any of the normal human tissues examined. To validate the expression pattern of this gene, we performed semi-quantitative RT-PCR using 10 clinical RCC cases and confirmed that SEMA5B was up-regulated in all of the 10 RCC cases examined, but its expression was undetectable in normal renal cortex (Fig. 3A) . Subsequent Northern blot analysis using a SEMA5B cDNA fragment as a probe revealed that an approximately 5-kb transcript was highly expressed in RCC cell lines, A704, OS-RC-2, and TUHR14TKB, but was hardly detectable in RPTEC cells derived from normal human renal proximal tubule epithelial cells (Fig. 3B, upper panel) , or in normal human tissues except fetal brain and kidney (Fig. 3B, lower  panel) . Expression of this gene was not elevated frequently in cancers of the breast, esophargus, lung, colon, bladder, pancreatic or prostate cancer according to our previous expression profile data (data not shown).
To obtain the full-length cDNA sequence of SEMA5B, we performed RT-PCR using RCC cell lines, OS-RC-2 or A704, Table V . Genes commonly down-regulated in RCC. -
We selected genes whose normalized expression ratios (RCC/normal renal cortex cells) were <0.2 in >50% of the 15 RCC cases examined. Accession numbers, gene symbols, and gene names were retrieved from the Unigene Database.
- was three nucleotides shorter than that of the V1 at the 3' end, and exon 20 of V2 was also three nucleotides shorter than that of V1 at the 5' end. Exon 21 of V2 was 131 nucleotides longer than that of V1 at the 3' portion, generating an earlier stop codon within exon 22. The translational initiation codon for both variants is commonly present in exon 2. To examine which variant was dominantly expressed in ccRCC cells, we performed RT-PCR experiments and found that SEMA5BV1 was highly up-regulated in ccRCC cells, whereas SEMA5BV2 was undetectable in all RCC cell lines (Fig. 3D) . Hence, we further perform functional analysis for the SEMA5BV1 transcript.
Inhibition of growth of RCC cells by specific small-interfering RNA against SEMA5B. To assess whether SEMA5B is essential for growth or survival of RCC cells, we constructed plasmids to express siRNAs against SEMA5B (si-#1 and si-#2) as well as control plasmids (siRNAs for Scramble and Mock vector), and transfected each of them into OS-RC-2 RCC cell line, which endogenously express high levels of SEMA5B mRNA. Among the siRNA constructs examined, si-#2 effectively reduced expression of SEMA5B mRNA compared with control siRNAs (si-Scramble and si-Mock) (Fig. 4A) . We observed significant decreases in the number of colonies (Fig. 4B ) and in the numbers of viable cells measured by MTT assay for the cells treated with si-#2 (Fig. 4C ). To exclude a possibility of off-target effect by SEMA5B-siRNA (si-#2), we generated two forms of siRNA with 3-bp replacement and found that neither of them suppressed SEMA5B expression in OS-RC-2 cells (data not shown). These findings indicated an important role of SEMA5B in RCC cell survival and/or growth.
Discussion
Recent progress in molecular biology has improved our understanding of the genesis of a wide range of human neoplasms. In RCC, several groups have reported microarray-based molecular profiling (12, (20) (21) (22) (23) (24) (25) . Although these studies have highlighted candidate genes that might be useful as diagnostic markers, data based on expression of mRNAs isolated from tumor masses might not exactly reflect changes during the course of renal carcinogenesis since tumor masses are generally mixtures of various cell populations such as inflammatory cells, stroma cells, and fibroblasts in addition to cancer cells and the proportions of each cell type vary significantly from one individual to another. In addition, RCCs is considered to originate from renal proximal tubule epithelial cells in renal cortex. Therefore, microarray data published previously are likely to have been influenced significantly by cellular heterogeneity among control preparations. In this study, we performed laser microbeam microdissection (LMM) to obtain pure populations of renal cancer cells as well as control normal renal cortex cells. Compared with one representative expression profile data of clear cell RCC (ccRCC) using RNAs from bulk tumor tissues by means of micorarray (21) , only 4 of the 85 (5%) genes which were commonly up-regulated in >75% of informative ccRCC cases in our data (Table IV) were overlapped to bulk-expression profile data (21) . These discrepancies were attributed to the fact that RCC cells are histopathologically heterogeneous, and expression profiles from bulk tissues could be significantly influenced by contamination with non-cancerous cells. Surprisingly, none of the top 24 genes that were most significantly up-regulated in our gene list (Table IV) was included in the previous results of ccRCC-expression profiles from bulk tissues (12, 21) . This evidence suggests our microarray data are much reliable as compared with others. We attribute this discrepancy to the fact that previous expression profiles from bulk cells could be significantly influenced by contamination of renal medullas in normal kidney tissues used as a control. For example, genes highly expressed in renal medulla, but not in renal proximal tubule epithelial cells in renal cortex, may be selected as downregulated or unchanged genes in expression profiles from bulk tissues. Taking these points into consideration, it is crucial to perform the LMM system to purify as much as possible the populations of cancerous and normal epithelial cells obtained from surgical specimens. Genes with altered expression in most of ccRCCs may serve as molecular diagnostic markers and candidates of RCC-therapeutic targets or may play causal roles in renal carcinogenesis. Among up-regulated genes, NNMT (nicotinamide N-methyltransferase), IGFBP3 (insulin-like growth factor binding protein 3), ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase 3), VEGF (vascular endothelial growth factor), and VWF (Von Willebrand factor) were included in our study as well as others. NNMT has been reported to be more frequently increased in ccRCCs than in other types of RCCs and to correlate with good prognosis in RCCs (12) . It was shown by immunohistochemical staining that IGFBP-3 leads to dysregulation of the IGF-axis within ccRCC (27, 28) . IGFP-3 was also shown to be involved in the regulation of RCC cell proliferation in an autocrine manner (27, 28) . Ecto-nucleotide pyrophosphatase/phosphodiesterase-I enzyme (ENPP), cleaves phosphodiester and phosphosulfate bonds of a variety of substrates. Mammalian ENPP comprises a family of three closely related proteins: ENPP1, ENPP2, and ENPP3. The function of ENPP3 is unknown, but it was reported that the expression of ENPP3 was higher in tumor tissues than in surrounding tissues and the specific form of the ENPP3 protein was detected in the sera of patients with bile duct carcinoma (BDC) and that ENPP3 enhanced cell migration. Therefore, ENPP3 may be related to the invasiveness of neoplastic BDC and can be applicable as a tumor marker (29) . Serum VEGF and VWF levels were indicated to be predictive markers for immunomodulatory agents including interleukin-2 and IFN-·; the patients with higher levels of VEGF and VWF revealed poor response to these treatments comparing to those showing lower serum levels of these proteins (15) . Furthermore, ABCG1 [ATPbinding cassette, sub-family G (WHITE), member 1] and STC2 (stanniocalcin 2) ABCG1, mediates the transport of cholesterol in general. ABCG1 was reported to be up-regulated in head and neck squamous cell carcinoma by microarray analysis and differential display (29) .
On the contray, among the down-regulated genes, WT1 (Wilms tumors 1), CDKN1C (cyclin-dependent kinase inhibitor 1C), and GAS1 (growth arrest-specific 1), have been implicated in growth suppression or apoptosis (16) (17) (18) (19) . Niu et al have reported that expression of WT1 was significantly downregulated in RCC tumors as compared with corresponding normal kidney tissues (16) , although no significant correlation was noted between the mRNA level and the clinicopathological features of RCCs. CDKN1C has been known to induce cell cycle arrest by inhibiting the activity of cyclin dependent kinases. Epigenetic silencing of this gene has been reported in solid tumors such as colorectal, gastric, hepatocellular, and pancreatic cancers (17) , suggesting that CDKN1C functions as a tumor suppressor gene. GAS1 was also significantly downregulated in 14 of 15 cases in this study. Induction of GAS1 has been reported to suppress cell proliferation and/or leading to apoptosis in neuron cells, and expression of GAS1 decreased glial proliferation (19) .
Among the up-regulated genes in our list, in this study we focused on Semaphorin 5B (SEMA5B) as a possible molecular target for RCC therapy due to frequent transactivation in RCCs and its undetectable level of expression in any of the normal human adult tissues we examined. We demonstrated that the knock-down of its expression level with siRNA resulted in the specifically significant suppression of RCC cell growth, suggesting its essential role in enhancement of cell growth. SEMA5B is a family of cell-surface and secreted glycoproteins that belong to a diverse group of genes encoding growth guidance cues (32) . Semaphorins and their receptors, plexins, were originally identified in the nervous system, where they are required to establish the correct neuronal network. Their repertoire has been expanded to several non-neural processes, including cardiac and skeletal development, the immune response and epithelial morphogenesis. More recently, semaphorins have been implicated in tumour growth and metastasis (33) . We demonstrated that SEMA5B is frequently expressed in the clear cell type of RCC as well as RCC cell lines, implying that targeting the SEMA5B might be a promising approach for development of novel therapeutic drugs.
Taken together, the up-regulated genes identified through our precise RCC-expression profiles should shed light on a better understanding of renal carcinogenesis and provide useful information to discover possible novel molecular targets for development of RCC treatment and also diagnostic tumor markers.
